Current Lymphoma News and Events

Current Lymphoma News and Events, Lymphoma News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called ''immunotherapies.'' But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging approaches, scientists from the Institut Pasteur and Inserm visualized in real time how anti-CD20 antibodies, used to treat B-cell lymphoma, guide the immune system to attack tumor cells. (2021-02-21)

Surface testing for SARS-CoV2 in hematology/oncology settings reveals negligible detection
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. (2021-02-18)

Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (2021-02-17)

Moffitt researchers identify why CAR T therapy may fail in some lymphoma patients
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma. (2021-02-02)

Cholesterol starvation kills lymphoma cells
Scientists have developed a novel therapy to trick cancer cells into gobbling up what they think is their favorite food - cholesterol -- which actually triggers their destruction. What appears to them as a cholesterol-loaded particle is actually a synthetic nanoparticle that binds to the cancer cells and starves them to death. The study was in lymphoma cells but could be effective in ovarian and kidney cancer. (2021-01-25)

Scientists make pivotal discovery on mechanism of Epstein-Barr virus latent infection
Wistar Researchers have discovered a new enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, a critical factor in EBV's ability to transform human cells and cause cancer. Study provides new indications for inhibiting EBNA1 function, opening up fresh avenues for development of therapies to treat EBV-associated cancers. (2021-01-21)

Target of new cancer treatment valid for breast as well as blood cancers: study
Newly published research shows that a new anti-cancer drug developed at the University of Alberta, set to begin human trials this year, may work against breast cancer as well as blood cancer. (2021-01-20)

UNH researchers discover new inhibitor drug combination for rare form of cancer
Researchers at the University of New Hampshire took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the Waldenström macroglobulinemia cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options. (2021-01-14)

A potent weapon against lymphomas
MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults. (2021-01-11)

Oncotarget: HIV +/- patients with lymphoma as a predictor of outcome & tumor proliferation
The Oncotarget author's hypothesis is that ADC values will inversely correlate with Ki-67 expression and that tumors with higher ADC values above the median will have improved OS and PFS (2021-01-11)

Scientists create ON-OFF switches to control CAR T cell activity
Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects. (2021-01-06)

New virtual screening strategy identifies existing drug that inhibits Covid-19 virus
A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational Biology. (2020-12-31)

Scientists unlock promising key to preventing cancer relapse after immunotherapy
The researchers discovered that cancer immunotherapies that make use of immune system cells such as T cells and CAR-T cells kill not only tumor cells that express the drugs' target, but also adjacent tumor cells that lack the targets, because of the presence of fas. This process, known as bystander killing, can be made more effective by adding therapeutics that turn off the regulation of fas proteins, the researchers said. (2020-12-17)

Potential treatment approach kills lymphoma while sparing healthy cells
Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes. (2020-12-16)

PET imaging tracer proves effective for diagnosing and managing rare CNS B-cell lymphoma
Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine. (2020-12-10)

CRISPR-edited CAR T cells enhance fight against blood cancers
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers. (2020-12-07)

Circulating tumor DNA indicates risk of relapse after transplant in DLBCL patients
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse. (2020-12-07)

CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments. (2020-12-06)

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (2020-12-05)

Scientists describe the role of a p53 target gene in lymphoma and lung cancer development
An international team of scientists has studied whether Zmat3 could have critical functions that p53, the most important gene in preventing cancer, uses to prevent cancer. Their findings have shifted the focus of how Zmat3 could function in tumor development. (2020-11-27)

New cancer drugs saved over 1.2 million people in the US over 16 years, new study shows
More than 1.2 million people in the US prevented facing death following a cancer diagnosis, between the year 2000 and 2016, thanks to ever improving treatment options -- a large new national study shows. (2020-11-09)

The natural artistry of disease: a wintry landscape in the eye
Researchers from Tokyo Medical and Dental University (TMDU) report a case of frosted branch angiitis in a woman presenting years after being treated for leukemia-lymphoma with allogeneic human stem cell transplant. The relevance of this ocular finding is discussed and its value as an early warning sign of immune activation following therapeutic immunological interventions is highlighted. (2020-11-09)

Study in Nature Medicine shows superior patient outcomes in LLS's Beat AML clinical trial
Study in Nature Medicine shows superior outcomes for patients in LLS's paradigm-shifting beat AML clinical trial. (2020-10-27)

Oncotarget: An integrative microenvironment approach for follicular lymphoma
Oncotarget Volume 11, Issue 33 features Figure 8, ''Haplotype estimates in follicular lymphoma patients,'' by Assis-Mendonça, et al. which reported that the authors tested associations between SNPs, clinicopathological features and TME composition, and proposed survival models in R-CHOP/R-CVP-treated patients. (2020-10-26)

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications. (2020-10-22)

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial. (2020-10-14)

Anticancer compounds for B cell cancer therapy targeting cellular stress response
Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (2020-10-13)

VAV1 gene mutations trigger T-cell tumors in mice
Researchers at the University of Tsukuba have shown how mutations in the VAV1 gene may trigger T-cell neoplasia in laboratory mice. Using cutting-edge research techniques including generation of specific transgenic mice models, tumor cell transplantation, whole transcriptome analysis, whole exome sequencing and in vivo treatment, the team was able to clarify the molecular pathways of T-cell tumor formation. These experimental protocols and animal models may be useful in evaluating novel treatments for such tumors. (2020-10-11)

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (2020-10-08)

Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (2020-10-06)

Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects. (2020-10-05)

Stop Livin to make lymphoma cells stop living
Researchers at the University of Tsukuba have shown that the protein Livin, an inhibitor of apoptosis or programmed cell death, mediates resistance to immunotherapy in some lymphoma variants. Therapeutically targeting Livin with IAP inhibitors or BET inhibitors may provide a practical strategy for patients with Livin-positive and other refractory B-cell lymphomas. (2020-09-16)

Oncotarget: ATM inhibition overcomes resistance to histone deacetylase inhibitor
The cover for issue 37 of Oncotarget features Figure 7, ''The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL,'' by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21. Paradoxically, the increased expression of p21 correlates with a reduced cell killing to the drug. (2020-09-16)

The Josep Carreras Institute identifies a marker of poor evolution in Hodgkin's lymphoma
Dr. Manel Esteller, director of the Josep Carreras Leukemia Research Institute, published today in Blood journal, the discovery of a marker that allows predicting which patient with Hodgkin's lymphoma will present the aggressive clinical course, and will therefore be a case of special risk. (2020-09-15)

Possible genetic link found between hypothyroidism and development of canine T-zone lymphoma
A genetic mutation might be the reason dogs with hypothyroidism are less likely to develop T-zone lymphoma (TZL). That's the finding from Morris Animal Foundation-funded researchers at Colorado State University who tried to identify genetic risk factors for TZL using a genome-wide association study (GWAS) and subsequent targeted sequencing. They recently published their results in the journal BMC Genomics. (2020-09-14)

Fighting cancer with rejection-resistant, 'off-the-shelf' therapeutic T cells
Baylor College of Medicine researchers develop improved cancer-fighting CAR T cells. (2020-08-20)

How viral infections associated with cancer become persistent?
A new study led by Pedro Simas, group leader at Instituto de Medicina Molecular (iMM; Portugal) and Kenneth M. Kaye, Professor at Harvard Medical School (HMS; USA), discovered a region of viral protein LANA that is key for viral latency and persistent infection inside human cells. These findings published today in the prestigious journal PNAS, can potentially be used to develop therapy for KSHV tumors since blocking the function of this LANA region is expected to abolish virus persistence, which would eliminate the cancer cells. (2020-08-17)

Singapore researchers discover genetic link to predict positive response to immunotherapy in patient
Findings offer cost and clinical benefits for patients with natural-killer T-cell lymphoma undergoing novel anti PD-1 therapy. Findings published in high impact factor journal, Leukemia. Discovery licensed to Singapore biotech company, Lucence Diagnostics which has developed diagnostic tests for clinical application. (2020-08-12)

Yale to lead trial of potential COVID-19 treatment
Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19. Known as LAM-002A (apilimod), the drug has a proven safety record. Preliminary research has shown it can block cellular entry and trafficking of the SARS-CoV-2 virus, the cause of COVID-19. (2020-07-27)

Excellent research results for CAR-T Cell therapy against Hodgkin lymphoma
Results from an early-phase clinical trial found CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, was highly active in patients with relapsed/refractory Hodgkin lymphoma. The treatment led to the complete disappearance of tumor in the majority of patients treated at the highest dose level of therapy with almost all patients having clinical benefit after treatment. (2020-07-23)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.